Restructuring Complete, Growth Reaccelerates: Q2 Revenue Up 13%, Net Income Attributable to SBC Medical Up 335%, Adjusted EBITDA(1) Up 32% Year-over-Year. AI-Enabled Service Enhancements Drive Successful Fee Increases, Positioning the Business for Accelerated Network Expansion
IRVINE, Calif.--(BUSINESS WIRE)--August 13, 2026--
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026).
Second Quarter 2026 Financial Highlights
-- Total revenues were $49 million, an increase of 13% year-over-year.
-- Net income attributable to SBC Medical was $11 million, an increase of
335% year-over-year. Net income margin was 22%, an increase of 16
percentage points year-over-year.
-- Adjusted EBITDA1 was $20 million, an increase of 32% year-over-year.
Adjusted EBITDA margin1 was 41%, an increase of 6 percentage points
year-over-year.
-- Basic EPS was $0.10 for the three months ended June 30, 2026, an
increase of 400% year-over-year.
The Company believes the quarter marked a clear reacceleration in its growth, with net income attributable to SBC Medical growth outpacing revenue growth. Earnings growth was supported by the expansion of the points business following a change in the Company's operating policy and the expansion of service fees in line with enhanced AI-enabled support capabilities.
The business of the medical corporations the Company supports also continued to expand steadily. As of the end of June 2026, the number of locations(2) increased by 34 year-over-year to 287, and last-twelve-month number of visits(3) reached 6.9 million (up 10% year-over-year). Average spend per visit was $287, up 9% year-over-year.
Comment from SBC Medical's Chairman and CEO Yoshiyuki Aikawa:
"We believe our results this quarter clearly demonstrate that SBC Medical's growth story has entered a new phase. Having completed the structural reforms we undertook in 2025, we are now running multiple growth engines simultaneously. I am growing increasingly confident that this reacceleration is not a temporary phenomenon but reflects the strengthening of our underlying growth fundamentals.
What gives me the greatest confidence is that the convergence of healthcare and AI is becoming one of SBC Medical's next sources of competitive advantage. We are leveraging more than 26 years of accumulated management data to support AI development and implementing mechanisms that enhance clinic operations -- including AI-powered call centers, AI-driven marketing, and AI-assisted site selection for new clinic openings.
Strengthening our AI-enabled MSO platform simultaneously drives growth across three dimensions: the number of clinic locations, average fee per clinic (AFPC), and service menu breadth. As the platform's appeal grows, patient visits and treatment volumes at the clinics we support increase, accelerating clinic growth -- which in turn leads to expanded service fees commensurate with the value we provide. We believe this virtuous cycle is the driving force behind sustainable growth in consolidated revenue and EPS, as reflected in our most recent reported historical results and in the future.
Specifically, through fee revisions for our call center services provided to five specific affiliated medical corporations, together with separate fee revisions reflecting expanded support for Rize Clinic and Gorilla Clinic, we expect these initiatives, if their impact is realized for a full year, to increase service fees by approximately $15 million annually (converted at Yen158.1/US$). These initiatives are being pursued in a disciplined manner, premised on a win-win relationship between the Company and our affiliated medical corporations.
Looking ahead, we will deepen our multi-brand strategy in aesthetic dermatology domestically, while expanding our non-aesthetic business, which we position as our "second growth engine." Internationally, we plan to accelerate our global growth through our collaboration with OrangeTwist in the United States and our ASEAN expansion, anchored in Thailand. We are also preparing to enter the Longevity market, which we see as having enormous potential.
With $184 million in cash and cash equivalents on hand, we will continue to pursue disciplined investment toward our next growth phase. By pursuing sustained EPS growth and achieving fair equity valuation for our shares in the capital markets as two wheels of the same cart, we aim to deliver even greater value to all our stakeholders, including our shareholders. We look forward to what lies ahead for SBC Medical."
Summary of Key Financials
Unit 2Q26 2Q25 YoY 1H26 1H25 YoY
---------------------------------- ---- ---- ---- ----- ---- ---- -----
Total revenues $MM 49 43 +13% 92 91 +2%
---------------------------------- ---- ---- ---- ----- ---- ---- -----
Net Income Attributable to SBC
Medical $MM 11 2 +335% 22 24 (8)%
---------------------------------- ---- ---- ---- ----- ---- ---- -----
Net Income Margin % 22 6 +16pt 24 26 (2)pt
---------------------------------- ---- ---- ---- ----- ---- ---- -----
Adjusted EBITDA (1) $MM 20 15 +32% 38 40 (4)%
---------------------------------- ---- ---- ---- ----- ---- ---- -----
Adjusted EBITDA Margin (1) % 41 35 +6pt 42 44 (2)pt
---------------------------------- ---- ---- ---- ----- ---- ---- -----
ROE (Annualized) (4) % 16 4 +12pt 17 22 (5)pt
---------------------------------- ---- ---- ---- ----- ---- ---- -----
Basic EPS (5) $ 0.10 0.02 +400% 0.21 0.23 (9)%
---------------------------------- ---- ---- ---- ----- ---- ---- -----
(1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial
measures. For more information on non-GAAP financial measures, please refer to
"Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP
Measures (unaudited)."
(2) Represents the total number of locations across the Company's support and
partnership network, including franchised locations of SBC-branded clinics,
Rize Clinic, Gorilla Clinic, AHH Clinic, JUN CLINIC, and OrangeTwist.
(3) Patient visits include patients of SBC-branded clinics, Rize Clinic,
Gorilla Clinic, AHH Clinic, and JUN CLINIC. The period covered is from July 1,
2025 to June 30, 2026.
(4) Return on equity $(ROE)$ is calculated as net income attributable to SBC
Medical divided by average shareholders' equity (beginning and end of
period).
(5) Basic EPS is calculated as net income attributable to SBC Medical divided
by the weighted average number of shares outstanding.
Conference Call
The Company will hold a conference call on Thursday, August 13th, 2026 at 08:30 a.m. Eastern Time (or Thursday, August 13th, 2026 at 09:30 p.m. Japan Time) to discuss the financial results for the second quarter ended June 30, 2026. A question-and-answer session will follow the prepared remarks.
During the live webcast, participants may submit questions in real-time using the Zoom Q&A button.
All attendees, regardless of their current stock ownership status, are welcome to submit questions. Please note that due to time constraints and the nature of the inquiries, we may not be able to address every question during the call.
Please register in advance of the conference using the link provided below:
https://zoom.us/webinar/register/WN_sEGnJWOyQDejlpnuGnxQgA
Upon registration, you will be able to access the dedicated conference call viewing site.
Additionally, the earnings release, accompanying slides, and a separate link to the archived webcast of this conference call will be available on the Company's Investor Relations website at https://ir.sbc-holdings.com/.
About SBC Medical
SBC Medical is a Medical Services Organization providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000$(R)$ Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose "Contributing to the well-being of people around the world through medical innovation," SBC Medical continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
Company Name: SBC Medical Group Holdings Incorporated | Listed Market: NASDAQ Global Market | Ticker: SBC | Address: 200 Spectrum Center Drive, Suite 300, Irvine, CA 92618 USA | IR Website: https://ir.sbc-holdings.com/ | LinkedIn: https://www.linkedin.com/company/sbc-medical-group-holdings-inc
Use of Non-GAAP Financial Measures